Element Biosciences is a company that develops and provides DNA sequencing technology and solutions for genomic research and applications.

Element Biosciences

Watchmaker Genomics develops high-performance next-generation sequencing products for various applications including inherited disease and somatic oncology, rare variant detection, ctDNA analysis, transcriptomics, epigenetics, and single-cell assays.

Watchmaker Genomics

Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multiomics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries.

Janus Henderson Investors

JS Capital Management

Logos Capital

Meritech Capital Partners

Counterpoint Global

Fidelity

Fidelity Management and Research Company

T. Rowe Price

Venrock

RA Capital Management

Foresite Capital

Missed the second installment of our 2024 Shift Your Science webinar series? Watch it now on-demand to delve into the revolutionary AVITI24™ system, redefining sequencing as we know it.

Learn how AVITI24 pushes benchtop sequencing into the next frontier by re-imagining core sequencing components and discover how Teton™ CytoProfiling allows you to analyze DNA, RNA, proteins, phosphorylated proteins, and cell morphology simultaneously, from just one sample in <24 hours.

Watch it now for insights into the future of sequencing! https://bit.ly/3XtcZPk

#ElemBio #AVITI24 #ShiftYourScience #Genomics #Multiomics #Sequencing #BioTech #NGS

We are pleased to announce the closing of our $277m Series D investment round. This funding will support the continued commercialization of AVITI™ and bolster the launch of AVITI24™, our revolutionary multi-omics powered sequencer.

Thank you to our new and existing investors at Wellington Management, Samsung Electronics, Fidelity Investments, Foresite Capital, T. Rowe Price, and Venrock, among others. We are grateful for your support of Element’s mission to empower the scientific community with cutting-edge innovation. https://bit.ly/4f0a4Ue

#ElemBio #AVITI #Innovation #AVITI24 #Sequencing #Genomics #ResearchInnovation #Multiomics #LifeScience

We are pleased to announce Annie K. as the winner 🏆of the AVITI™ for Oncology grant, jointly offered by Element and AmpSeq!  Dr. Kathuria will utilize AVITI sequencing to characterize novel 3D organoid models for biomarker discovery and therapeutic screening. Learn more about AVITI sequencing: https://bit.ly/3Lgrn5R

#ElemBio #AVITI #OncologyGrant #Sequencing #OncologyResearch #CancerResearch

Join us at Single Cell Congress Asia 2024 to explore AVITI24™️, our innovative platform that integrates advanced sequencing and cytoprofiling. Discover how Element's flexible, upgradable systems can enhance your single cell research. Visit Booth 6 to speak with Element & Sciencewerke Pte Ltd representatives to learn more. https://bit.ly/3Ye6n7R

#Singlecell #Elembio #AVITI #AVITI24 #ShiftYourScience #Sequencing #ResearchInnovation #Genomics

🚀 Flexible, high-quality sequencing and cytoprofiling solutions 🚀

The AVITI™ system family empowers researchers with cutting-edge sequencing technology, unparalleled performance, and flexibility to upgrade as your applications and throughput needs grow. 

🧬 AVITI24 combines state-of-the-art sequencing and Teton™ CytoProfiling into a single platform so you can simultaneously analyze DNA, RNA, proteins, and cellular morphology from a single sample.
🧬 AVITI performs cost-effective, high-quality sequencing with a flexible throughput, saving you time and resources.
🧬 AVITI LT is a low-throughput version of AVITI, ideal for smaller-scale projects or labs with a small range of applications or limited capital equipment budget.

🔍 Discover the AVITI family: https://bit.ly/3xGWGnn

#ElemBio #AVITI #AVITI24 #Sequencing #Genomics #GenomeSequencing #ResearchInnovation

Don’t miss the Front Line Genomics webinar series, Multiomics Unleashed to explore the latest advancements in multiomics.

Join us at Webinar 2: Enhancing Your Multiomic Workflows with Data Integration where Abbey Cutchin, Associate Director, Strategic Marketing will share how the AVITI24™ uses Teton™ Chemistry to empower multiomic cytoprofiling and cell analysis.

📅 Tuesday, July 16 2024
🕒 10:00 AM EDT | 3:00 PM BST | 4:00 PM CET

Secure your spot: https://bit.ly/3zt5wFM

#ElemBio #AVITI #Multiomic #AVITI #Genomics #Sequencing #Cytoprofiling #ResearchInnovation

Metric
Company Name	Element Biosciences	Watchmaker Genomics
Symbol
MSH ID	COM:ELEMENTBIOSCIENCES	COM:WATCHMAKERGENOMICS
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Series A
Employee Count	349
Website	elementbiosciences.com	watchmakergenomics.com
LinkedIn	elembio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		2.34K
Web Traffic Growth		-0.52
Valuation
Raised Capital		40M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ELEMENTBIOSCIENCES

Element Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue